1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Prince Pharmaceutical Co., Ltd.

Prince Pharmaceutical Co., Ltd.

6935.TWO
Prince Pharmaceutical Co., Ltd.TW flagTaipei Exchange
30.30
TWD
+0.05
- -
1.13BMarket Cap
Prince Pharmaceutical Co., Ltd.
6935.TWO
(Taipei Exchange)

Recent

price

30.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
FRC
7.79
9.04
13.29
21.47
22.7
19.07
- -
Revenue per Share
- -
-1.03
-0.25
1.55
0.46
-1.48
- -
Basic EPS, GAAP
-5.46
-5.71
0.03
2.16
0.01
0.78
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.16
0.25
- -
Dividend per Share
11.03
10.13
9.55
11.13
12.52
9.57
- -
Book Value per Share
19.3
18.59
18.1
19.79
23.29
19.94
- -
Tangible Book Value per Share
32
33
33
33
33
36
- -
Basic Weighted Avg Shares
250
296
441
713
753
690
1,056
Sales/Revenue/Turnover
-3.73
-17
-0.25
9.52
3.41
-7.15
10.5
Operating Margin (%)
14
28
46
52
59
62
62
Depreciation Expense
- -
-34
-8
52
15
-54
96
Net Income, GAAP
35.71
- -
- -
19.7
20.12
- -
8.04
Effective Tax Rate (%)
- -
-11.43
-1.88
7.24
2.03
-7.76
9.12
Profit Margin (%)
-106
28
74
112
179
130
251
Working Capital
102
409
486
455
424
390
354
LT Debt
620
611
603
658
774
722
839
Total Equity
- -
- -
- -
4.64
1.67
- -
8.32
Return on Invested Capital (%)
- -
- -
- -
6.62
2.63
- -
12.38
Return on Capital (%)
- -
-9.87
-2.56
15.02
3.9
-14.06
23.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
6.99%
16.15%
Free Cash Flow
- -
3,484.92%
152.57%
Net Income, GAAP
- -
-319.27%
-279.9%
Sales/Revenue/Turnover
- -
32.21%
53.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
753
2024
- -
- -
- -
- -
690
2025
- -
- -
- -
- -
1,056

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.46
2024
- -
- -
- -
- -
-1.48
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.16
2024
- -
- -
- -
- -
0.25
2025
- -
- -
- -
- -
- -
Similar Companies
Teyi Pharmaceutical Group Co.,Ltd (002728.SZ)
Procaps Group S.A. (PROC)
ManifestSeven Holdings Corporation (MNFSF)
Elanco Animal Health Inc (ELAT)
Herborium Group, Inc. (HBRM)
Organogenesis Holdings Inc. (ORGO)
Business
Prince Pharmaceutical Co., Ltd. (6935.TWO) manufactures active pharmaceutical ingredients, primarily vitamin B1 derivatives, and health food products. The company produces vitamin B1 APIs compliant with USP, JP, and JPC pharmacopoeias; health foods via OEM operations; and western medicines including formulations such as injections, tablets, capsules, ointments, and powders. It operates APIs production facilities in Hsinchu Industrial Park, food factories in Xinpu and additional sites in Hsinchu County, with headquarters in Huwei Township, Yunlin County, Taiwan; founded in 1962, it supplies products to Taiwan, Japan, Europe including Spain, South Korea, Singapore, and other markets. Certifications encompass PIC/S GMP, cGMP, ISO 9001, ISO 22000, HACCP, GMP, and TQF for its plants. Nanpao Group became a shareholder in 2016, marking a key ownership change; the company completed product development in 2017 and reported health food sales growth to NT$554 million in 2024 alongside western medicine revenues, reflecting sustained operations in its core segments.